Pulmonary Arterial Hypertension

For this analysis, the Japan Pulmonary Hypertension Registry provided data from 2008 to 2021 on patients with diagnosed portopulmonary hypertension (PoPH).

The study investigators wanted more data on long-term outcomes in pediatric patients following implantation of a transcatheter Potts shunt (TPS) for treatment of severe pulmonary arterial hypertension (PAH).

Researchers investigated outcomes following implementation of remote care that targeted effective control of hypertension, or elevated blood pressure (BP), and cholesterol management.

Despite the commonality of hypertension among US adults—nearly half of them have elevated blood pressure—hypertension education among internal residents has not kept up with the condition’s prevalence.

This investigation involved analyses of the potential for pulmonary hypertension (PH) and interstitial lung disease (ILD) to have an impact on patients living with systemic sclerosis.

Two data sets from patients with severe pulmonary arterial hypertension (PAH) show the benefits of macitentan (Opsumit) monotherapy despite guidelines calling for combination therapy, even among patients with World Health Organizational functional class I-II disease.

According to the study authors, acute decompensated pulmonary hypertension (PH) is often accompanied by systemic congestion and right ventricular flow output, and because PH can be accompanied by acute kidney injury, renal replacement therapy (RRT) may be necessary.

Although group 1 pulmonary arterial hypertension (PAH) with comorbid syncope has been linked to a poor prognosis among adults, this relationship remains uncertain in pediatric patients, prompting a new study.

Investigators for this study analyzed outcomes among patients hospitalized with pulmonary arterial hypertension (PAH) who have higher risks of adverse health outcomes, in particular sepsis and septic shock.

This study evaluated pregnancy-related outcomes among women with pulmonary hypertension (PH) ranging from mild to severe in disease severity.

Outcomes following right heart catheterization in a pediatric patient population were analyzed, with emphasis placed on risk of adverse outcomes following the procedure, especially the development of pulmonary hypertensive crisis (PHC).

Researchers used 2011-2020 data to examine age- and race-/ethnicity-related trends in hypertension diagnosis, with implications for future cardiovascular disease care.

This new study of pulmonary arterial hypertension (PAH) among women examined the in-common symptoms of different disease phenotypes to see where they overlap and ultimately to define the “symptome” according to symptom cluster and characteristics.

Following a recent update to the diagnostic criteria for borderline pulmonary hypertension (PH), which is often associated with left heart failure (LHF), outcomes among patients with both conditions remain uncertain.

This open-label extension of the SERAPHIN trial evaluated the long-term safety and tolerability of a small daily dose of the endothelin receptor antagonist against pulmonary arterial hypertension (PAH) among patients from the original study.

The rates of 3 hypertensive disorders were compared among 2 groups of women: those who gave birth between 1995 and 1999 vs 2015 to 2019.

Infants born between the 23rd and 25th weeks of pregnancy, classified as extremely low gestational age newborns, are surviving in increasing numbers, note study authors, and with that is growing clinical interest in their long-term sequelae, including pulmonary hypertension (PH).

Investigators found significant shifts in diagnosis of and prescriptions for pulmonary hypertension (PH) when exercise right heart catheterization was used.

Clinicians interviewed in a recent study reported various social determinants of health (SDOH) affecting health outcomes for patients with pulmonary arterial hypertension (PAH), indicating the need to address SDOH in PAH care.

Several measures of hemodynamic capacity were improved in this study that evaluated sacubitril/valsartan use for heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH).

A Belgian study compared exercise performance before and after COVID-19 lockdown measures were swiftly implemented in the country among patients with preexisting pulmonary arterial hypertension (PAH).

Researchers have found that patients who have idiopathic pulmonary arterial hypertension (IPAH) with a phenotype characterized by a smoking history and low diffusion capacity for carbon monoxide had little in common with patients with classical IPAH.

Despite current guidelines recommending combination therapy, there are certain patients with pulmonary arterial hypertension (PAH) who remain on monotherapy for specific reasons.

Collecting more than 3 decades’ worth of data, researchers determined that none of the identified blood biomarkers are accurate enough to take the place of current diagnostic approaches, either due to lack of data or lack of specificity.

Based on their findings, the researchers of the retrospective study are calling for close evaluation, careful monitoring, and appropriate treatment to mitigate complications and mortality.

Drugs currently marketed for pulmonary arterial hypertension have been able to extend the lives of patients but have shown limitations in their ability to prevent or reverse the disease. A novel combination approach may hold promise in future treatments.

A new commentary suggests new pathways might lead to a major shift in the treatment of pulmonary arterial hypertension (PAH).

A new review article shows positive trends in survival, as scientists better understand the different types and symptoms of pulmonary arterial hypertension (PAH).

The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with sildenafil.